Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Martin Schrappe,Franco Locatelli,Maria Grazia Valsecchi,Gunnar Cario,Michaela Vossen-Gajcy,Jan Stary,Andishe Attarbaschi,Nicole Bodmer,Draga Barbaric,Sarah Elitzur,Daniela Silvestri,Alexandra Kolenova,Anja Moericke,Jean-Pierre Bourquin,Luciano Dalla-Pozza, Martin Stanulla,Shai Izraeli,Carmelo Rizzari,Fiona Poyer,Arend von Stackelberg, Valentino Conter, Martin Zimmermann, Andrea Biondi

BLOOD（2023）

引用 0|浏览11

暂无评分

摘要

Background: One of the key questions in trial AIEOP-BFM ALL 2017 focused on the reduction of treatment-related complications by replacing parts of the highly intensive consolidation phase by two courses of Blinatumomab (Blina) in a prospective randomized trial. Herein, we report the toxicity profile of B-cell acute lymphoblastic leukemia (B-ALL) patients (pts) with high-risk (HR) characteristics pending final outcome data.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要